Osteolysis and drugs of ingredients of repaglinide (a real world drug study)
Summary:
Osteolysis is found among people who take drugs with ingredients of repaglinide, especially for people who are female, 50-59 old . This phase IV clinical study is created by eHealthMe based on reports of 12,681 people who have side effects when taking drugs with ingredients of repaglinide from the FDA, and is updated regularly.
Drug(s) considered in the study (i.e. both brand name and generic drugs): Prandin, Repaglinide.
12,681 people reported to have side effects when taking drugs with ingredients of repaglinide.
Among them, 43 people (0.34%) have Osteolysis
What is Osteolysis?
Osteolysis (dissolution of bone) is found to be associated with 689 drugs and 408 conditions by eHealthMe. Check the latest studies of Osteolysis.
Number of reports submitted per year:

Gender of people who have Osteolysis when taking drugs with ingredients of repaglinide *:
- female: 62.79 %
- male: 37.21 %
Age of people who have Osteolysis when taking drugs with ingredients of repaglinide *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 62.79 %
- 60+: 37.21 %
Conditions people have *:
You may use this to check any potential undetected conditions.
- Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 27 people, 62.79%
- Osteoporosis (bones weak and more likely to break): 27 people, 62.79%
- Multiple Myeloma (cancer of the plasma cells): 14 people, 32.56%
- Thrombocytopenia (decrease of platelets in blood): 11 people, 25.58%
- Insomnia (sleeplessness): 3 people, 6.98%
- Metastases To Bone (cancer spreads to bone): 2 people, 4.65%
- Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 2.33%
- Metastatic Neoplasm (spreadable cancer tumour): 1 person, 2.33%
- Hypersensitivity: 1 person, 2.33%
- Breast Cancer Metastatic: 1 person, 2.33%
Other drugs people take *:
You may use this to check any potential interacting drugs.
- Percocet: 43 people, 100.00%
- Zometa: 43 people, 100.00%
- Aredia: 42 people, 97.67%
- Dilaudid: 42 people, 97.67%
- Lasix: 35 people, 81.40%
- Ambien: 28 people, 65.12%
- Levaquin: 28 people, 65.12%
- Mobic: 28 people, 65.12%
- Nexium: 28 people, 65.12%
- Flexeril: 27 people, 62.79%
Other side effects people have besides Osteolysis *:
You may use this to check any potential undetected side effects.
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 43 people, 100.00%
- Swelling: 43 people, 100.00%
- Acute Kidney Failure: 42 people, 97.67%
- Bone Pain: 42 people, 97.67%
- Tooth Disorder (tooth disease): 42 people, 97.67%
- Osteomyelitis (infection of bone): 42 people, 97.67%
- Pain: 42 people, 97.67%
- Sinusitis (inflammation of sinus): 40 people, 93.02%
- Spinal Osteoarthritis (joint cartilage loss in spine): 39 people, 90.70%
- Osteoarthritis (a joint disease caused by cartilage loss in a joint): 37 people, 86.05%
* Approximation only. Some reports may have incomplete information.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related studies
Drugs with ingredients of repaglinide, their effectiveness, alternatives and more:
How the study uses the data?
The study uses data from the FDA. It is based on repaglinide. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Potassium cause Cholecystitis? - 4 seconds ago
- Clarithromycin and Insomnia for Women aged 30-39 - 17 seconds ago
- Clarithromycin and Can'T Sleep for Women aged 30-39 - 17 seconds ago
- Clarithromycin and Agrypnia for Women aged 30-39 - 17 seconds ago
- Clarithromycin and Insomnia Concerns for Women aged 30-39 - 17 seconds ago
- Clarithromycin and Difficulty Falling Asleep for Women aged 30-39 - 18 seconds ago
- Clarithromycin and Sleeplessness for Women aged 30-39 - 18 seconds ago
- Clarithromycin and Inability To Sleep for Women aged 30-39 - 18 seconds ago
- Clarithromycin and Sleeping for Women aged 30-39 - 19 seconds ago
- Clarithromycin and Sleep Aid for Women aged 30-39 - 19 seconds ago